(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 499.2% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.86%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.25%.
Nrx Pharmaceuticals's revenue in 2026 is $3,394,000.On average, 7 Wall Street analysts forecast NRXP's revenue for 2026 to be $2,622,338,016, with the lowest NRXP revenue forecast at $182,448,362, and the highest NRXP revenue forecast at $10,974,178,061. On average, 7 Wall Street analysts forecast NRXP's revenue for 2027 to be $8,657,854,527, with the lowest NRXP revenue forecast at $254,579,110, and the highest NRXP revenue forecast at $25,209,826,251.
In 2028, NRXP is forecast to generate $37,534,832,243 in revenue, with the lowest revenue forecast at $23,607,882,872 and the highest revenue forecast at $51,998,216,167.